News and Announcements
ISAG – Placement to Strategic Investor
- Published September 23, 2013 1:51PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
Indoor Skydive Australia Group Limited ACN 154 103 607 (ASX:IDZ) (“Company”) has agreed to a placement under section 708(8) of the Corporations Act 2001 (Cth) to a key strategic investor.
The placement is for 2,225,000 shares at an issue price of $0.45 to raise $1,001,250. The placement will be settled on Thursday 26 September 2013. As the placement will be settled after the record date for the Renounceable Pro-Rata Entitlements Offer (“Offer”) the recipient will not be entitled to participate in the Offer. The placement is within the 15% limit set out in Listing Rule 7.1 and does not require shareholder approval.
Veritas Securities Limited acted as Corporate Advisor to the Company for the Share Placement.
The Company believes that this placement is a key step in consolidating the IDZ financial position while greatly increasing its capacity to more rapidly deliver on the vision and strategy detailed in the Company’s Prospectus.
To read the full ASX Release please click on the document below.
Company Updates
Capital Is Flowing – Just Not to Everyone: Inside Australia’s $1.8 Billion Q1 2026
Australia’s startup ecosystem opened 2026 with a number that demanded attention. In the first three months of the year, $1.8 billion was raised across 81 venture deals and 26 accelerator rounds. That makes Q1 2026 the strongest start to a year since the 2022 boom, up 63% on Q1 2025, and more than double the […]
The control layer for the electrified home
THE MARKET SHIFT Australian households have been pulled into a real-time energy market they never knowingly signed up for. Flat electricity tariffs are disappearing. In their place: dynamic, time-of-use pricing that changes depending on when power is consumed. Electricity is now cheapest when solar floods the grid in the middle of the day — and […]
500 Million Episodes, Limited Treatment: How Patrys is Bridging the Gap in an Underserved Market
In the clinical vocabulary of the Intensive Care Unit, there is perhaps no word that carries as much quiet dread as delirium. It is a “chemical storm” of the brain—an acute dysfunction where the delicate balance between calming and activating signals is scrambled. For the patient, it can be a waking nightmare of hallucinations and […]
Backed By Leading Investment Groups and Family Offices
